OSUR ORASURE TECHNOLOGIES INC
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1116463 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-7.5%
TTM net income YoY19.5%
TTM EPS YoY14.8%
Revenue 3-yr CAGR-36.4%
Net income 3-yr CAGR—
Margins
Gross margin43.1%
Operating margin-43.8%
Net margin-41.7%
FCF margin-42.7%
EBITDA margin-35.8%
Returns
ROE-14.5%
ROA-12.6%
ROIC (approx.)-26.4%
Asset turnover0.30x
Leverage & solvency
Liabilities / assets12.1%
Debt / equity0.00x
Current ratio8.58x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.90x
Accruals ratio-1.2%
Payout ratio—
Capex / revenue5.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $115.02M | $185.83M |
| Cost of revenue | $66.82M | $106.44M |
| Gross profit | $48.20M | $79.39M |
| R&D expense | $42.53M | $26.05M |
| SG&A expense | $47.68M | $46.22M |
| Operating income | -$71.97M | -$28.25M |
| Pretax income | -$64.59M | -$16.00M |
| Income tax | $1.80M | $1.80M |
| Net income | -$68.73M | -$19.50M |
| EBITDA | -$61.78M | -$17.38M |
| EPS (basic) | -0.94 | -0.26 |
| EPS (diluted) | -0.94 | -0.26 |
| Weighted avg. shares (diluted) | 73.48M | 74.43M |
| Balance sheet | ||
| Cash & equivalents | $199.28M | $267.76M |
| Receivables | $22.20M | $23.82M |
| Inventory | $31.06M | $34.20M |
| Current assets | $261.91M | $333.22M |
| PP&E, net | $39.18M | $45.10M |
| Goodwill | $43.36M | $40.33M |
| Intangibles | $19.05M | $17.43M |
| Total assets | $403.17M | $479.66M |
| Current liabilities | $39.80M | $33.48M |
| Total liabilities | $62.34M | $69.32M |
| Shareholders' equity | $340.83M | $410.34M |
| Shares outstanding | 70.39M | 74.60M |
| Cash flow statement | ||
| Operating cash flow | -$49.02M | $27.37M |
| Capital expenditure | $4.20M | $3.80M |
| Free cash flow | -$53.22M | $23.58M |
| Investing cash flow | -$6.81M | -$39.03M |
| Financing cash flow | -$16.94M | -$4.18M |
| Depreciation & amortization | $10.19M | $10.87M |
| Stock-based compensation | $10.15M | $11.92M |
| Share buybacks | $15.04M | $0 |
Free plan shows the latest 2 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.